drugset / Trial / NCT02397213

Ciclosporin to Protect Renal Function In Cardiac Surgery

NCT02397213 ↗

Phase 2 Completed 155 enrolled Region Skane NeuroVive Pharmaceutical AB · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to evaluate the potential of ciclosporin in reducing risk and degree of acute kidney injury after cardiac surgery.

Timeline

Start
2015-04
Primary completion
2016-05
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cyclosporine Peptide 2.5 mg/kg Intravenous

Indications